The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Ikena Oncology; Innovent Biologics; SK Life Sciences
Research Funding - Alexion Pharmaceuticals; Alexo Therapeutics; Alkermes; Alpine Immune Sciences; Alpine Immune Sciences; Apexian Pharmaceuticals; Asana Biosciences; Ascentage Pharma; Astellas Pharma; BeiGene; Celgene; Celgene; Cerulean Pharma; Constellation Pharmaceuticals; Coordination Therapeutics; CytomX Therapeutics; Epizyme; Formation Biologics; Forty Seven; Genmab; Gilead Sciences; GlaxoSmithKline; Helsinn Therapeutics; Ikena Oncology; Ikena Oncology; Incyte; InhibRx; Innovent Biologics; Innovent Biologics; Jounce Therapeutics; LAM Therapeutics; Lilly O.; Livzon; Loxo; MacroGenics; Merck; Mersana; Northern Biologics; Odonate Therapeutics; Pfizer; Regeneron; Sapience Therapeutics; Seagen; Seagen; Servier; Shattuck Labs; Shattuck Labs; Symphogen; Tesaro; Tizona Therapeutics, Inc.
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Karl D. Lewis
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Consulting or Advisory Role - Merck; Regeneron
Research Funding - Merck/Genentech (Inst); Regeneron (Inst)
 
Amy M. Weise
Employment - N/A
Leadership - N/A
Stock and Other Ownership Interests - N/A
Honoraria - N/A
Consulting or Advisory Role - N/A
Speakers' Bureau - N/A
Research Funding - N/A
Patents, Royalties, Other Intellectual Property - N/A
Expert Testimony - N/A
Travel, Accommodations, Expenses - N/A
Other Relationship - N/A
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Accutar Biotech (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); OncoC4 (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
John Crown
Employment - OncoAssure; OncoMark
Stock and Other Ownership Interests - OncoAssure; OncoMark
Honoraria - AstraZeneca; MSD Oncology; Pfizer; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - Pfizer
Research Funding - BMS GmbH & Co. KG (Inst); MSD Oncology (Inst); Novartis (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Astrazeneca; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Regeneron; Roche
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Natera; Novartis; Pfizer
 
Eugenia Girda
No Relationships to Disclose
 
John M. Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Bicara Therapeutics; Coherus Biosciences; Rakuten Medical
 
Kevin B. Kim
Honoraria - Bristol-Myers Squibb; Genentech; Novartis; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis; Regeneron; Sanofi
 
Nehal Lakhani
No Relationships to Disclose
 
Melinda Lynne Yushak
Research Funding - Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst)
 
Jayakumar Mani
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Fang Fang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Laura Brennan
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Vladimir Jankovic
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Anne Josee Paccaly
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Sheila Masinde
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Giuseppe Gullo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron